139 related articles for article (PubMed ID: 37113049)
21. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Huntington SF; Manzoor BS; Puckett JT; Kamal-Bahl S; Alhasani H; Ravelo A; Jawaid D; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2316-2323. PubMed ID: 37732602
[TBL] [Abstract][Full Text] [Related]
22. The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
Keating NL; Brooks GA; Landrum MB; Liu PH; Wolf R; Riedel LE; Kapadia NS; Jhatakia S; Tripp A; Simon C; Hsu VD; Kummet CM; Hassol A
J Natl Cancer Inst; 2022 Jun; 114(6):871-877. PubMed ID: 35134972
[TBL] [Abstract][Full Text] [Related]
23. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
24. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
[TBL] [Abstract][Full Text] [Related]
25. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
[TBL] [Abstract][Full Text] [Related]
26. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
29. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
30. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia.
Clark SE; Marcum ZA; Radich JP; Bansal A
J Oncol Pharm Pract; 2021 Dec; 27(8):1842-1852. PubMed ID: 33175653
[TBL] [Abstract][Full Text] [Related]
31. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
32. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
[TBL] [Abstract][Full Text] [Related]
33. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous occurrence of chronic lymphocytic and chronic myeloid leukemia.
Katović SK; Vasilj A; Maricević I; Carzavec D; Jurić SC
Coll Antropol; 2010 Jun; 34(2):653-5. PubMed ID: 20698147
[TBL] [Abstract][Full Text] [Related]
35. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Wu EQ; Johnson S; Beaulieu N; Arana M; Bollu V; Guo A; Coombs J; Feng W; Cortes J
Curr Med Res Opin; 2010 Jan; 26(1):61-9. PubMed ID: 19905880
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
Davis TC; Arnold CL; Mills G; Lesser GJ; Brown WM; Schulz R; Weaver KE; Pawloski PA
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769563
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
[TBL] [Abstract][Full Text] [Related]
38. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
[TBL] [Abstract][Full Text] [Related]
39. Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel.
Iyengar RN; LeFrancois AL; Henderson RR; Rabbitt RM
J Manag Care Spec Pharm; 2016 May; 22(5):550-60. PubMed ID: 27123916
[TBL] [Abstract][Full Text] [Related]
40. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
